ProShare Advisors
ARQT icon

ProShare Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

ProShare Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$500K Sell
19,087
-2,412
-11% -$56.2K ﹤0.01% 1095
2026
Q1 		$507K Sell
21,499
-4,026
-16% -$103K ﹤0.01% 1055
2025
Q4 		$741K Buy
25,525
+2,941
+13% +$75.3K ﹤0.01% 925
2025
Q3 		$426K Sell
22,584
-3,830
-14% -$60.4K ﹤0.01% 1202
2025
Q2 		$370K Sell
26,414
-2,208
-8% -$31K ﹤0.01% 1296
2025
Q1 		$448K Sell
28,622
-7,195
-20% -$101K ﹤0.01% 1155
2024
Q4 		$499K Buy
35,817
+8,833
+33% +$96.8K ﹤0.01% 1276
2024
Q3 		$251K Buy
26,984
+9,245
+52% +$91.2K ﹤0.01% 1582
2024
Q2 		$165K Sell
17,739
-3,251
-15% -$29.4K ﹤0.01% 1572
2024
Q1 		$208K Buy
20,990
+1,870
+10% +$14K ﹤0.01% 1652
2023
Q4 		$61.8K Buy
19,120
+8,412
+79% +$22.9K ﹤0.01% 1837
2023
Q3 		$56.9K Buy
10,708
+47
+0.4% +$400 ﹤0.01% 1702
2023
Q2 		$102K Buy
+10,661
New +$118K ﹤0.01% 1696
2023
Q1 		– Sell
-10,379
Closed -$154K – 1797
2022
Q4 		$154K Buy
+10,379
New +$181K ﹤0.01% 1557
2022
Q2 		– Sell
-10,401
Closed -$200K – 1813
2022
Q1 		$200K Sell
10,401
-2,726
-21% -$46.1K ﹤0.01% 1888
2021
Q4 		$272K Sell
13,127
-1,148
-8% -$22.9K ﹤0.01% 1844
2021
Q3 		$341K Sell
14,275
-1,922
-12% -$43.8K ﹤0.01% 1454
2021
Q2 		$442K Buy
16,197
+3,069
+23% +$86.4K ﹤0.01% 1616
2021
Q1 		$380K Buy
13,128
+1,809
+16% +$56.5K ﹤0.01% 1642
2020
Q4 		$318K Buy
+11,319
New +$277K ﹤0.01% 1570

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

ProShare Advisors's ARQT Position: Q2 2026 in Review

ProShare Advisors reduced its Arcutis Biotherapeutics (ARQT) stake by 11% in Q2 2026, selling an estimated $56.2K and leaving 19,087 shares worth $500K. The position accounts for ﹤0.01% of the portfolio, ranked #1095.

ProShare Advisors first reported a position in ARQT in Q4 2020 and has held it in 20 quarters since. The position peaked at $741K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • ProShare Advisors held 19,087 shares of Arcutis Biotherapeutics worth $500K as of Q2 2026.
  • ProShare Advisors sold 2,412 Arcutis Biotherapeutics shares in Q2 2026, an estimated $56.2K.
  • Arcutis Biotherapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1095 holding.
  • ProShare Advisors first reported a position in Arcutis Biotherapeutics in Q4 2020 and has held it in 20 quarters since.
  • ProShare Advisors's Arcutis Biotherapeutics position peaked at $741K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.